Synthetic Stock: How Ackman Doubled-Down on VRX
November 26, 2015 at 14:00 PM EST
Some may get tired of hearing about Bill Ackman and Valeant Pharma, but I think studying this investment – its ups, downs, tricks, and traps – is a fascinating study in both the power of derivatives and that of investing bias.